Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gamma-Delta T Cells in Preventing Relapse After Allogeneic Transplantation in High-risk AML
NCT07123662Phase 1Withdrawn
- Sponsor
- Guangzhou Bio-gene Technology Co., Ltd.
- Start
- Sep 2025
- Primary completion
- May 2028
- Modality
- Cell Therapies
01
Overview
Phase 1, randomised, single-blind trial of gamma-delta T cells in acute myeloid leukemia (AML) (2 arms), sponsored by Guangzhou Bio-gene Technology Co., Ltd. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 12 months. Planned start Sep 2025; status: withdrawn.
02
Drugs
gamma-delta T cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07123662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07123662.